Wang Xiaowen, Luke Alina A, Vader Justin M, Maddox Thomas M, Joynt Maddox Karen E
Cardiovascular Division, Department of Medicine, Washington University School of Medicine, St. Louis, MO (X.W., A.A.L., J.M.V., T.M.M., K.E.J.M.).
Cardiovascular Division, Department of Medicine, Brigham and Women's Hospital, Boston, MA (X.W.).
Circ Cardiovasc Qual Outcomes. 2020 Jun;13(6):e006284. doi: 10.1161/CIRCOUTCOMES.119.006284. Epub 2020 May 12.
Left ventricular assist device (LVAD) therapy is an increasingly viable alternative for patients who are not candidates for heart transplantation or who are waiting for a suitable donor. We aimed to determine whether there is an association between sex, race/ethnicity, insurance coverage, and neighborhood income and access to/outcomes of LVAD implantation. We further analyzed whether access to LVAD improved in states that did versus did not expand Medicaid.
Retrospective cohort study using State Inpatient Databases to identify patients 18 to 85 years of age admitted for heart failure, cardiogenic shock, or LVAD implantation from 2012 to 2015. Logistic regression analyses adjusting for age, all the sociodemographic factors above, medical comorbidities, and a hospital random effect were used to quantify odds of receipt of LVADs, as well as outcomes conditional on receiving an LVAD, for the sociodemographic groups of interest. A total of 925 770 patients were included; 3972 (0.43%) received LVADs. After adjusting for age, comorbidities, and hospital effects, women (adjusted odds ratio [aOR], 0.45 [0.41-0.49]), black patients (aOR, 0.83 [0.74-0.92]), and Hispanic patients (aOR, 0.74 [0.64-0.87]) were less likely to receive LVADs than whites. Medicare (aOR, 0.79 [0.72-0.86]), Medicaid (aOR, 0.52 [0.46-0.58]), and uninsured patients (aOR, 0.17 [0.11-0.25]) were less likely to receive LVADs than the privately insured, and patients in low-income ZIP codes were less likely than those in higher income areas (aOR, 0.71 [0.65-0.77]). Among those who received LVADs, women (aOR, 1.78 [1.38-2.30]), patients of unknown race or race other than white, black, or Hispanic (aOR, 1.97 [1.42-2.74]), and uninsured patients (aOR, 4.86 [1.92-12.28]) had higher rates of in-hospital mortality. Medicaid expansion was not associated with an increase in LVAD implantation.
There are meaningful sociodemographic disparities in access and outcomes for LVAD implantation. Medicaid expansion was not associated with an increase in LVAD rates.
对于不适合进行心脏移植或正在等待合适供体的患者,左心室辅助装置(LVAD)治疗正成为越来越可行的替代方案。我们旨在确定性别、种族/族裔、保险覆盖范围、邻里收入与LVAD植入的可及性/结果之间是否存在关联。我们还进一步分析了在扩大医疗补助的州与未扩大医疗补助的州,LVAD的可及性是否有所改善。
采用回顾性队列研究,利用州住院数据库识别2012年至2015年因心力衰竭、心源性休克或LVAD植入而入院的18至85岁患者。使用逻辑回归分析,对年龄、上述所有社会人口学因素、合并症以及医院随机效应进行调整,以量化目标社会人口学群体接受LVAD的几率以及接受LVAD后的结果。总共纳入了925770名患者;3972名(0.43%)接受了LVAD。在对年龄、合并症和医院效应进行调整后,女性(调整后的优势比[aOR],0.45[0.41 - 0.49])、黑人患者(aOR,0.83[0.74 - 0.92])和西班牙裔患者(aOR,0.74[0.64 - 0.87])接受LVAD的可能性低于白人。医疗保险患者(aOR,0.79[0.72 - 0.86])、医疗补助患者(aOR,0.52[0.46 - 0.58])和未参保患者(aOR,0.17[0.11 - 0.25])接受LVAD的可能性低于私人保险患者;低收入邮政编码地区的患者接受LVAD的可能性低于高收入地区的患者(aOR,0.71[0.65 - 0.77])。在接受LVAD的患者中,女性(aOR,1.78[1.38 - 2.30])、种族不明或非白人、黑人或西班牙裔的患者(aOR,1.97[1.42 - 2.74])以及未参保患者(aOR,4.86[1.92 - 12.28])的院内死亡率较高。医疗补助的扩大与LVAD植入的增加无关。
在LVAD植入的可及性和结果方面存在显著的社会人口学差异。医疗补助的扩大与LVAD植入率的增加无关。